von Bergmann K, Fierer J, Mok H Y, Grundy S M
Antimicrob Agents Chemother. 1981 Feb;19(2):342-5. doi: 10.1128/AAC.19.2.342.
Because the action of rifampin induces hepatic microsomal enzymes, a study was carried out in four patients to determine whether this drug alters the composition of biliary lipids. Several different measurements were made while patients were both on and off rifampin therapy for various infective processes. These measurements included multiple determinations of lipid composition of gallbladder bile, the relative proportions f individual bile acids, and kinetics of cholic acid and chenodeoxycholic acid. In all four patients, the saturation of gallbladder bile increased during rifampin treatment, and the bile consistently became supersaturated. The relative portions of chenodeoxycholic acid and cholic acid were essentially unchanged by treatment, but total synthesis of bile acids increased in three tested patients with rifampin therapy. These results indicate that rifampin increases saturation of bile with cholesterol, but this increase is not due to a reduction in bile acid production.
由于利福平的作用会诱导肝微粒体酶,因此对四名患者进行了一项研究,以确定该药物是否会改变胆汁脂质的组成。在患者接受利福平治疗以应对各种感染性疾病的过程中,以及停药期间,进行了几种不同的测量。这些测量包括对胆囊胆汁脂质组成的多次测定、各个胆汁酸的相对比例,以及胆酸和鹅去氧胆酸的动力学。在所有四名患者中,利福平治疗期间胆囊胆汁的饱和度增加,胆汁持续变得过饱和。治疗后鹅去氧胆酸和胆酸的相对比例基本未变,但在三名接受利福平治疗的受试患者中,胆汁酸的总合成增加。这些结果表明,利福平会增加胆汁中胆固醇的饱和度,但这种增加并非由于胆汁酸生成减少所致。